THLD MNTA AINV VHC RSO TORM DMND GMCR APKT AMSC
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WLT still being dragged to woodshed kicking and screaming..
in tiny 6.66..lol
FNMA 4.13..waaaa..coulda had another 100 freebies..gonna sell these out of spite,lol
spoke too soon..in PLUG 6.66..lmao..tiny
yup, looks like da boys wanna take WLT to 8..nuts!..speaking of which DMND reports a/h..sucker doubled in a year
Chu called up Citron and they tagteamed PLUG
crazy ..u see the size on some of the asks as it was dropping?sheesh..now u get it back on bounce to 5 while I whineee
just noticed PLUG 6.66 wag almost filled earlier..pfft
4.02..waaa
3.97..its close, I should have been more patient but was nice and quick, hope u get it all back and then some
someday maybe..but not today,lol
boinggg out cost basis 3.80/5..250 freebies..whew
ridiculous size on some of these sellers..sheesh
WLT add 8.98
dip to 3.26 and no fill..grrrrrrr..edit there it is
WLT under 9..where to add..
is a bit..
PLUG unplugged..fannie and freedie too
sorry J..tiny FNMA nibble 3.70's..add set 3.33
Market just a tad toppy..lol..some tiny UVXY for shiggles
WLT still sucking wind
Dark side of the moon
VIPS -$7
Pac Crest upgrades Apple on iPhone 6 hopes
Pac Crest's Andy Hargreaves has upgraded Apple (AAPL) to Outperform, and set a $635 PT. He thinks a 4.7" iPhone 6 will arrive in the fall (in-line with reports), and that a base model will sell for a relatively steep subsidized price of $299; that could imply an unsubsidized price of $749.
Hargreaves estimates a 4.7" iPhone could boost the iPhone's total FY15 (ends in Sep.) unit sales by 10M to 170.4M, while lifting its ASP by $36 to $641 and its EPS contribution by $4 to $33.04.
He isn't counting on a 5.5" iPhone (also rumored to be in the pipeline) arriving this year. At the same time, he thinks new product launches (an iWatch?) provide "optionality" to Apple shares.
Hargreaves downgraded Apple on Jan. 16, 2013; when shares were at $471
Bayer extends collaboration..Bayer (BAYRY) signs multi-year extension with Roche's (RHHBY) Ventana Medical Systems to develop companion diagnostics focused on immunohistochemistry.
The agreement focuses on the development of diagnostic tests for Bayer's biomarker-targeted therapeutics.
Ventana will create an expert team with resources exclusively designated for Bayer.
Financial terms are undisclosed.
Big Pharma lobbies Australia to extend poppy growing
GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and TPI Enterprises want the government of Australia to let them grow poppies on the country's mainland, due to a shortage of opium for pain killers and amid soaring demand.
Australia only allows poppy growing in Tasmania, which is responsible for around half of the world's supply of opiate-based pain relief. Recent drought and storms in Tasmania have meant that drug firms can't get enough crops.
I wish..barf
Teen retail malaise lingers on
Weak reports from Urban Outfitters (URBN) and American Eagle Outfitters (AEO) could cast a pall over the entire teen apparel sector.
Both retailers say they are very cautious on Q1 results after seeing weather clip traffic and the holiday promotional activity linger on.
On watch: ARO, PSUN, PLCE, ANF, CHS, BKE, ZUMZ, EXPR.
Sanofi, UCB team up to develop drugs for inflammatory diseases
Sanofi (SNY) is partnering with Belgium's UCB to develop anti-inflammatory small molecules that could be used "to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis."
Sanofi will make upfront and milestone payments that have the potential to surpass €100M.
The companies will share costs and profits on a 50-50 basis.
The agreement is the latest example of a major pharmaceutical company looking externally for new drugs.
http://www.fiercebiotech.com/press-releases/sanofi-and-ucb-partner-breakthrough-innovation-immune-mediated-diseases
Premarket Gainers / Losers
Gainers: LJPC +70%. CDTI +63%. SNMX +22%. RNN +21%. RCON +17%. FCEL +16%. UQM +15%. SCON +15%. BYD +14%. ZBB +14%. CPST +12%. BLDP +11%. PLUG +9%. OPTT +8%. QTWW +8%. JCP +7%. PPHM +7%. NWBO +6%. NVAX +5%. .
Losers: FTEK -19%. AEO -5%. MYGN -5%. TESO -5
Premarket Gainers / Losers
Gainers: LJPC +70%. CDTI +63%. SNMX +22%. RNN +21%. RCON +17%. FCEL +16%. UQM +15%. SCON +15%. BYD +14%. ZBB +14%. CPST +12%. BLDP +11%. PLUG +9%. OPTT +8%. QTWW +8%. JCP +7%. PPHM +7%. NWBO +6%. NVAX +5%..
Losers: FTEK -19%. AEO -5%. MYGN -5%. TESO -5
bullish or bulls..t?
SNMX Senomyx announces approval of Sweetmyx flavor ingredient by FDA
SNMX ripping
GM Z +SSS
CDTI big rip
Rexahn cancer drug safe so far in Phase I study, shares jump
Rexahn's (RNN) Supinoxin (RX-5902) has so far shown to be "safe and well-tolerated" in an ongoing Phase I trial of patients with solid cancer tumors, with no drug-related side-effects reported.
A fourth dosing cycle has been initiated following the completion of three cycles.
In animal testing, treatment with Supinoxin resulted in a significant reduction in tumor growth.
Shares jump 14.9%
http://seekingalpha.com/pr/9222593-rexahn-announces-initial-results-from-phase-i-trial-of-supinoxintm-rxminus-5902-for-solid-cancer-tumors
InterMune upgraded
Goldman Sachs upgrades InterMune (ITMN) to Buy with a price target of $45 citing better-than-expected top line Phase 3 results for pirfenidone.
11 of 14 analysts rate the company at least Buy.
Consensus revenue estimates for 2014 and 2015 are $137M and $316M, respectively.
lol..LJPC quite the trader for u guys..4 buck bounce off p/m lows in 15's..now fading a bit
GM BC..Tesla faces a roadblock in New Jersey
Tesla Motors (TSLA) says Governor Christie’s administration in New Jersey is pushing forward legislation that will curtail its ability to conduct sales in the state.
Christie is a strong proponent of blocking the direct sales model of Tesla in favor of requiring the use of a third-party dealer.
The EV automaker has had success in blocking similar legislation proposals in other states, but New Jersey could be a tough nut to crack.
TSLA -0.8% premarket